Gossamer Bio GOSS 深 滬
已收盤 02-06 16:00:00 美东时间
2.26
-0.175
-7.19%
華盛通- 最 高2.50
- 今 開2.475
- 成交量 793.18万股
- 最 低 2.23
- 昨 收 2.435
- 總市值 5.23亿
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 3.43%
- 52周最低 0.76
- 委 比 -96.49%
- 總股本 2.31亿
- 歷史最高 27.15
- 量 比 1.22
- 振 幅 11.09%
- 歷史最低 0.4525
- 每 手 1
- 風險率 0.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price target.
01-22 19:55
Oppenheimer’s best small and mid-cap ideas for 2026
Oppenheimer Research released a list of its best ideas for small-caps and mid-caps in the new year. Analysts said that, absent the traditional warning signs that have historically preceded market down...
01-07 00:59
Gossamer Bio Enters Merger Agreement with Respira
An announcement from Gossamer Bio ( ($GOSS) ) is now available. On September 24...
2025-09-25 21:18
Cantor Fitzgerald Reiterates Overweight on Gossamer Bioto Overweight
Cantor Fitzgerald analyst Olivia Brayer reiterates Gossamer Bio (NASDAQ:GOSS) from Overweight to Overweight.
2025-09-11 20:32
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
2025-09-11 10:06
UBS Upgrades Gossamer Bio to Buy, Raises Price Target to $9
UBS analyst Eliana Merle upgrades Gossamer Bio (NASDAQ:GOSS) from Neutral to Buy and raises the price target from $1.25 to $9.
2025-09-10 18:44
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
2025-08-07 09:46
Gossamer shares are trading lower. The company reported Q2 financial results.
Gossamer shares are trading lower. The company reported Q2 financial results.
2025-08-07 00:57
